ALK on my mind: alectinib takes an early lead in managing intracranial disease in non-small cell lung cancer with ALK rearrangements

Ann Transl Med. 2017 Apr;5(7):173. doi: 10.21037/atm.2017.03.47.

Authors

Phu N Tran¹, Samuel J Klempner^{2

3}

Affiliations

¹ Division of Hematology-Oncology, University of California Irvine, Orange, CA, USA.
² The Angeles Clinic and Research Institute, Los Angeles, CA, USA.
³ Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

No abstract available

Publication types

Editorial
Comment